Asymptomatic Hyperuricemia: A Nephro-Rheumatological Perspective.
Autor: | Moszczuk B; Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland., Życińska K; Department of Rheumatology, Systemic Connective Tissue Diseases and Rare Diseases, Central Clinical Hospital MSWiA in Warsaw, Warsaw, Poland.; Department of Family Medicine, Medical University of Warsaw, Warsaw, Poland., Mucha K; Department of Transplantology, Immunology, Nephrology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.; Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland. |
---|---|
Jazyk: | angličtina |
Zdroj: | Archivum immunologiae et therapiae experimentalis [Arch Immunol Ther Exp (Warsz)] 2024 Nov 29; Vol. 72 (1). Date of Electronic Publication: 2024 Nov 29 (Print Publication: 2024). |
DOI: | 10.2478/aite-2024-0024 |
Abstrakt: | Hyperuricemia (HU) is a common disorder associated with gout, kidney injury, and high cardiovascular risk. However, whether high serum uric acid (sUA) is a causative factor or just comorbidity remains unclear. When asked if asymptomatic hyperuricemic patients need treatment, even artificial intelligence in the form of the GPT chat provides an ambivalent answer and refers us to a healthcare provider. We believe that such discrepancies stem from an incomplete understanding of the role that uric acid (UA) plays inside and outside the cell. With the rapid development of genomics, proteomics, immunology, and novel biomarkers, we are armed with new data to help us better understand the weight of inborn and environmental factors on an individual's UA concentrations. This review sums up the latest progress that has been made in the field of asymptomatic HU, compares the results presented by various research teams, and indicates new directions that emerge for future studies. (© 2024 Barbara Moszczuk et al., published by Sciendo.) |
Databáze: | MEDLINE |
Externí odkaz: |